Home / Generics / General / Generics applications under review by EMA – December 2015

Generics applications under review by EMA – December 2015 Posted 05/02/2016

Generic medicines in Europe can be approved either centrally via the European Medicines Agency (EMA) or nationally via the local regulatory body [1]. Approval by EMA takes place by using a centralized procedure. This leads to approval of the product in all 28 European Union (EU) Member States and in Iceland, Liechtenstein and Norway. At a country level, if approval in a single EU Member State only is required, this can take place using the national procedure. However, as soon as a company seeks approval in two or more Member States, a decentralized procedure or mutual recognition procedure must be used [2].

According to EMA’s list of applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP) released on 4 December 2015, the agency is currently reviewing 25 applications for marketing approval in the EU for generics. The applications include one for a generic version of Otsuka Pharmaceutical’s schizophrenia drug Abilify (aripiprazole), two for Janssen-Cilag’s multiple myeloma treatment Velcade (bortezomib), one for chemotherapy drug docetaxel (Taxotere, Sanofi), two for arthritis treatment methotrexate (Trexall, Pfizer) and one for Parkinson’s medicine rasagiline (Azilect, Teva), for which there are already generics approved in the EU, see Table 1.

Table 1: Generics under review by EMA*

Common name

Therapeutic area

Number of applications

Originator product

Originator company

Alendronic acid/colecalciferol

Osteoporosis

1

Fosavance/Vantavo

MSD

Amlodipine/valsartan

Renin-angiotensin (high blood pressure)

1

Exforge

Novartis

Aripiprazole

Psycoleptic (schizophrenia)

1

Abilify

Otsuka Pharmaceutical

Atazanavir

Antiretroviral (HIV treatment)

1

Reyataz

Bristol-Myers Squibb

Bortezomib

Antineoplastic (multiple myeloma)

2

Velcade

Janssen-Cilag

Caspofungin

Antimycotic (antifungal)

1

Candidas

Merck

Darunavir

Antiretroviral (HIV treatment)

1

Prezista

Janssen-Cilag

Docetaxel

Antineoplastic (chemotherapy)

1

Taxotere

Sanofi-Aventis

Emtricitabine/tenofovir disoproxil

Antiretroviral (HIV treatment)

2

Truvada

Gilead Sciences

Ertapenem

Antibacterial for systemic use

1

Invanz

Merck

Fluticasone/salmeterol

Obstructive airway disease (asthma/COPD)

2

Advair/Seretide

GlaxoSmithKline

Ivabradine

Cardiac therapy (angina)

1

Corlanor/Procoralan

Amgen/Servier

Methotrexate

Antineoplastic (cancer, arthritis)

2

Maxtrex

Pfizer

Miglustat

Metabolism (Gaucher disease)

1

Zavesca

Actelion

Palonosetron

Anti-emetic/anti-nauseant (prevention of chemotherapy-induced nausea and vomiting)

2

Aloxi

Helsinn Birex Pharmaceuticals

Pemetrexed

Antineoplastic (carcinoma, lung mesothelioma)

1

Alimta

Eli Lilly

Rasagiline

Parkinson’s disease

1

Azilect

Teva Pharmaceutical Industries

Tenofovir disoproxil

Antiretroviral (HIV treatment)

2

Viread

Gilead Sciences

Zonisamide

Anti-epileptic

1

Zonegran

Eisai

Total

 

25

   

*Data collected on 29 January 2016.
COPD: chronic obstructive pulmonary disease.
Source: EMA

First-time European generics under review by EMA include one for a generic version of MSD’s osteoporosis treatment Fosavance/Vantavo (alendronic acid/colecalciferol), one for a generic version of high blood pressure treatment Exforge (amlodipine/valsartan), one for a generic version of Bristol-Myers Squibb’s HIV treatment Reyataz (atazanavir), one for a generic version of Merck’s antifungal medication Cancidas (caspofungin), one for a generic version of Janssen-Cilag’s HIV treatment Prezista (darunavir), one for a generic version of Gilead Sciences HIV treatment Truvada (emtricitabine/tenofovir disoproxil), two for GlaxoSmithKline’s asthma and chronic obstructive pulmonary disorder treatment Advair/Seretide (fluticasone/salmeterol), one for a generic version of Actelion’s Gaucher disease treatment Zavesca (miglustat), two for generics of Helsinn Birex Pharmaceuticals treatment for chemotherapy-induced nausea and vomiting Aloxi (palonosetron), one for a generic version of Eli Lilly’s carcinoma drug Alimta (pemetrexed), two for generics of Gilead’s HIV treatment Viread (tenofovir disoproxil) and one for Eisai’s epilepsy treatment Zonegran (zonisamide).

Since the last report entitled Generics applications under review by EMA – August 2015 by GaBI Online, EMA has approved one generic version of Otsuka Pharmaceutical’s schizophrenia drug Abilify (aripiprazole), from generics company Sandoz. The agency has also approved a generic version of Amgen’s treatment for high calcium levels Mimpara (cinacalcet) from Mylan, one generic version of GlaxoSmithKline’s heart-attack prevention Intergrilin (eptifibatide) from Accord Healthcare, one for a generic version of AbbVie’s HIV treatment Kaletra (lopinavir/ritonavir) from Mylan and five for generics of Eli Lilly’s carcinoma drug Alimta (pemetrexed) from Accord Healthcare, Actavis, Hospira, Medac and Sandoz.

Related articles
Biosimilars applications under review by EMA – December 2015  

Generics applications under review by EMA – August 2015

References
1.   GaBI Online - Generics and Biosimilars Initiative. EU guidelines for generics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 5]. Available from: www.gabionline.net/Guidelines/EU-guidelines-for-generics  
2.   GaBI Online - Generics and Biosimilars Initiative. Registration procedures for generic drugs in the EU [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Feb 5] Available from: www.gabionline.net/Reports/Registration-procedures-for-generic-drugs-in-the-EU 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: EMA

Comments (0)